741265-15-6

Basic information

• Product Name: 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinonitrile
• Synonyms: 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinonitrile
• CAS NO: 741265-15-6
• Molecular Weight: 311.694
• Mol File: 741265-15-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinonitrile(741265-15-6)
• EPA Substance Registry System: 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinonitrile(741265-15-6)

Safety Data

• Hazardous Substances Data: 741265-15-6(Hazardous Substances Data)

Upstream product

• 59938-06-6 4-ethoxy-1,1,1-trifluoro-3-butene-2-one 
• 116548-04-0 2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile 
• 386704-06-9 2-chloro-6-(trifluoromethyl)nicotinonitrile 
• 95-79-4 5-chloro-2-methyl-benzenamine 

Downstream Products

• 741265-23-6 2-(5-chloro-2-methyl-phenylamino)-6-trifluoromethyl-nicotinic acid 
• 1018788-40-3 C₂₀H₁₁Cl₄F₃N₂O₂ 
• 1018788-38-9 C₂₀H₁₂Cl₃F₃N₂O₂ 
• 1018788-32-3 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-34-5 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-36-7 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-42-5 C₂₁H₁₆ClF₃N₂O₃ 

Relevant articles and documents

2-(Arylamino)-6-(trifluoromethyl)nicotinic acid derivatives: New HIV-1 RT dual inhibitors active on viral replication

The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC50 of 14 μM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects.

NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS

The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.